⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 1, 2025

Supplementary Figure 1 from Moxidectin Unravels the Role of the Hippo–YAP Pathway in Maintaining Immunity of Glioblastoma Multiforme

Itishree Kaushik Robin Rajan Shreyas Gaikwad Mohamed A. Eltokhy Sanjay Srivastava

View Full Paper

Ask AI

Bookmark

Share

Key Points

Moxidectin influences the hippo-yap pathway, crucial for immunity in glioblastoma multiforme.
MEK/ERK pathway analysis shows changes after 12 hours of moxidectin treatment.
The findings suggest a novel target for therapeutic strategies in glioblastoma.
Understanding this pathway may improve treatment options for patients with glioblastoma multiforme.

Implication

Supplementary figure reveals how moxidectin affects the hippo-yap pathway in glioblastoma, indicating its potential in enhancing immunity.

Abstract

Supplementary Figure 1: Effect of Moxidectin in MEK/ERK-YAP pathway after 12 hours of treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kaushik et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0235 https://doi.org/10.1158/1535-7163.29760431

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 3 from Moxidectin Unravels the Role of the Hippo–YAP Pathway in Maintaining Immunity of Glioblastoma Multiforme2025
2Supplementary Figure 2 from Moxidectin Unravels the Role of the Hippo–YAP Pathway in Maintaining Immunity of Glioblastoma Multiforme2025
3Data from Moxidectin Unravels the Role of the Hippo–YAP Pathway in Maintaining Immunity of Glioblastoma Multiforme2025
4Figure S4 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor2024
5Figure S5 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor2024